WNT and CDK4 inhibition might provide a potential therapeutic strategy for difficult-to-treat epithelial 35 tumors. 36 37 42 regression in animal models [7] [8] [9] [10] [11] [12] . We recently showed that restoring endogenous regulation of the WNT 43 pathway by re-expressing normal levels of APC, is sufficient to induce disease regression in established 44 colorectal cancers 8,9 . 45 Efforts to target WNT signaling pharmacologically have explored multiple nodes of inhibition, 46 including blocking WNT ligand secretion and direct targeting the downstream transcriptional effector, 47 b-catenin 13, 14 . We reasoned that modulating WNT signaling through the same mechanism by which 48 APC acts would provide the best opportunity for well-controlled WNT regulation. While it is not 49 feasible to genetically restore APC in human CRCs, it is possible to reinforce the activity of the 50 APC/AXIN/b-catenin destruction complex by increasing the levels of the scaffold proteins AXIN1/2. 51 Tankyrase enzymes (TNKS and TNKS2) are functionally-redundant members of the poly-ADP ribose 52 polymerase (PARP) family that mediate the PARsylation and degradation of AXIN1/2, and thus, TNKS 53 inhibition stabilizes AXIN and reinforces endogenous suppression of WNT signaling. Numerous small 54 molecules have been described that enable selective TNKS1/2 blockade and WNT pathway suppression 55 in CRC cell lines 15-18 . 56 Despite their ability to dampen hyperactive WNT and suppress tumor growth in model systems, TNKS 57 inhibitors do not always show anti-proliferative effects as single agents in human CRC cell lines 17,19,20 . 58 However, when mitogenic signaling is limited by the reduction of serum in the culture media, TNKS 59 inhibition can block growth and proliferation of otherwise resistant cells 16,21 . This suggests that 60 inhibition of parallel mitogenic signals may synergize with TNKS inhibitors to control tumor cell 61 growth. Indeed, blocking MEK, PI3K, or EGFR can enhance the anti-tumor effect of TNKS 62
Abstract 25
Tankyrase (TNKS) 1/2 are positive regulators of WNT signaling by controlling the activity of the b-26 catenin destruction complex. TNKS inhibitors provide an opportunity to suppress hyperactive WNT 27 signaling in tumors, however, they have shown limited anti-proliferative activity as a monotherapy in 28 human cancer cell lines. Here we perform a kinome-focused CRISPR screen to identify potential 29 effective drug combinations with TNKS inhibition. We show that the loss of CDK4, but not CDK6, 30 synergizes with TNKS1/2 blockade to drive G1 cell cycle arrest and senescence. Through precise 31 modelling of cancer-associated mutations using cytidine base editors, we show that this therapeutic 32 approach is absolutely dependent on suppression of canonical WNT signaling by TNKS inhibitors and 33 is effective in cells from multiple epithelial cancer types. Together, our results suggest that combined
Introduction 38
Almost all colorectal cancers (CRCs) carry activating mutations in the WNT pathway, most often due 39 to loss-of-function truncations in the adenomatous polyposis coli (APC) tumor suppressor 1,2 . Numerous 40 studies have shown that hyperactivation of the WNT pathway is an oncogenic driver in the intestine 3-5 , 41 and in many cases, suppression of WNT signaling is sufficient to induce cell differentiation 6 and tumor goal of defining combination approaches to enhance tumor cell response. We identify CDK4 as a 65 synthetic vulnerability in colorectal cancer cells and show that dual inhibition of TNKS and CDK4 66 drives a potent cell cycle arrest in a range of human epithelial cancer cell lines including colon, breast 67 and lung cancer cells. Recently, Lord and colleagues identified a novel TNKS1/2 inhibitor 68 (MSC2504877) and identified several synergistic targets through siRNA and drug-based screens, 69 including CDK4/6 23 . We demonstrate that this drug synergy is absolutely dependent on suppression of 70 canonical WNT signaling, and that the TNKS and CDK4 combined inhibition promotes enhanced 71 cellular senescence. Our findings support recent work with an independent TNKS inhibitor and 72 highlight the potential for WNT-targeted therapies to sensitize CRCs to FDA-approved CDK4/6 73 inhibitors.
75

Results 76
A kinome-focused screen identifies vulnerabilities in colorectal cancer 77 Tankyrase inhibition suppresses WNT signaling in diverse human and mouse cell types by stabilizing 78 AXIN1 protein, resulting in decreased stability of beta-catenin and subsequently reduced transcription 79 of TCF target genes 16, 17, [19] [20] [21] [24] [25] [26] (Fig 1a) , yet TNKS inhibition alone is not sufficient to decrease cell 80 proliferation in these cells under normal growth conditions 16, 20 (Supplementary Fig 1a) . However, in 81 low serum conditions (2% FBS), cells become sensitive to TNKS inhibition 21 (Fig 1b) . Similarly, 82 suppression of MAP kinase activity via MEK inhibition synergizes with TNKS blockade 17 (Fig 1c) . To 83 identify other potential signaling dependencies that drive TNKS inhibitor resistance, we set out to 84 evaluate the requirement for all human kinases, using a focused CRISPR-based loss-of-function screen.
85
We first identified a minimal dose of the TNKS inhibitor, XAV939 21 (hereafter XAV) that induced 86 maximal AXIN1 stabilization (Fig 1d) and confirmed that treatment with this dose (1uM) maintained 87 elevated AXIN1 levels up to 48hrs ( Supplementary Fig 1b) . We then generated stable Cas9-expressing 88 clones of the CRC line DLD1 (see Methods) and confirmed that each line (hereafter, LC9) could induce 89 rapid depletion of sgRNAs targeting essential genes (e.g. CDK1 or RPA3) 22 ; We chose the three most 90 efficient clones as replicates for the screen ( Supplementary Fig 2a) . As expected, prolonged treatment 91 of the clonal lines with 1uM XAV caused only a minor suppression in cell proliferation over three 92 weeks in culture (containing 10% serum) ( Supplementary Fig 2b) . effective inhibitors targeting CDK4/6 (Palbociclib, Ribociclib, and Abemaciclib), though none are yet 119 approved for CRC 28 .
120
To assess how specific this synergy was for CDK4, we compared gRNA depletion across the entire 121 CDK family in DMSO vs XAV-treated cells (Fig 2a) . While some CDK genes are known essential 122 fitness genes (i.e. CDK1, CDK7 or CDK9), other members had an intermediate impact (CDK2 and   123 CDK4), and some were completely dispensable for DLD1 cell proliferation (CDK5, CDK6, and 124 CDK10). Importantly, only CDK4 (and not the other closely related partner of Cyclin D, CDK6), 125 showed enhanced depletion in the presence of XAV (Table 1 and Supplementary Fig 5a) . We validated 126 the synergy between loss of CDK4 and TNKS inhibition using four independent CDK4 gRNAs 127 targeting CDK4, all of which reduced cell fitness in fluorescence-based competitive assays (Fig 2b and   128 2c). Consistent with the results from the screen, depletion of CDK6 using two effective gRNAs only 129 caused a minor disadvantage in competition assays, which was not significantly different between 130 DMSO or XAV-treated cells ( Supplementary Fig 5a and Fig 2a-c) . These results highlight a specific 131 CDK4 dependence upon TNKS inhibition in colorectal cancer cells.
132
To confirm the synthetic lethality observed upon inhibition of TNKS together with gRNA-mediated 133 CDK4 depletion was not specific to CRISPR-mediated CDK4 disruption, we treated DLD1 cells with 134 varying concentrations of XAV and the CDK4/6 inhibitor Palbociclib. As expected, we observed 135 increased suppression in colony formation following treatment with both drugs, that was greater than 136 the additive effects of each treatment alone (Fig 2d and 2e) . Conversely, to confirm the synergy 137 observed was due to direct TNKS suppression and not inhibition of other PARP family members, we 138 used two independent doxycycline(dox)-regulated shRNAs against TNKS1/2. As expected, shRNA-139 mediated depletion of TNKS sensitized DLD1 cells against Trametinib, Gefitinib and Palbociclib in the 140 presence of dox (Fig 2f and Supplementary Fig 5b) . Finally, we confirmed the on-target effect of TNKS 141 inhibition in sensitizing cells to CDK4 blockade by treating cells with commercially-available small 142 molecules that block TNKS activity via distinct mechanisms. TNKS inhibition through either the 143 nicotinamide subsite (XAV939), adenosine subsite (G007-LK) or via a dual adenosine and 144 nicotinamide binder (NVP-656), synergized with Palbociclib to suppress cell proliferation (Fig 2g) .
145
The synergy between TNKS and CDK4 inhibition was not restricted to DLD1 cells, as we observed 146 similar effects of TNKS silencing and Trametinib or Palbociclib treatment in the colorectal carcinoma 147 cell line SW480 (bearing an APC truncating mutation, similar to DLD1) (Fig 2f and Supplementary Fig   148   5c ). Further, we saw enhanced growth suppression in multiple breast and lung cancer cell lines treated 149 with XAV and Palbociclib, demonstrating a consistent combinatorial effect of TNKS and CDK4 150 blockade across a broad spectrum of cancer cell lines of epithelial origins ( Supplementary Fig 5d) .
152
Synergy of combined TNKS and CDK4/6 inhibition is dependent on WNT pathway suppression
153
TNKS has a number of PARsylation targets other than AXIN1/2, including telomere binding factor 154 TRF1 29 , the mitotic regulator NUMA1 30 , and YAP/TAZ-associated angiomotin (AMOT) proteins 27 , 155 among others. To determine whether TNKS/CDK4 inhibitor synergy was dependent on suppression of 156 WNT signaling we used CRISPR base editing to engineer an S45F missense mutation in endogenous 157 CTNNB1 31 in DLD1 cells, rendering it insensitive to regulation by the APC destruction complex. We 158 derived CTNNB1 S45F DLD1 clones and treated them with XAV (1uM) and increasing doses of 159 Palbociclib (10-1000nM). While XAV-treated parental cells were 3-fold more sensitive to Palbociclib 160 (IC50 250 for XAV-treated cells and 800nM for DMSO-treated cells, respectively), CTNNB1 S45F 161 isogenic cells showed no change in response to treatment with XAV (Fig 3a-d) . Similarly, XAV-162 treatment of a natural CTNNB1 S45F mutant cell line, HCT116, showed no increased sensitivity to 163 Palbociclib, or genetic disruption of CDK4 by CRISPR ( Supplementary Fig 6a-e ). These results suggest 164 that TNKS-mediated sensitization to CDK4 inhibition is absolutely dependent on the ability of TNKS 165 inhibitors to suppress WNT signaling. Importantly, we saw identical effects when XAV was combined 166 with Trametinib or Gefitinib, implying that most reported drug synergies with TNKS inhibitors are 167 likely mediated through WNT suppression ( Supplementary Fig 6a-f ).
169
Tankyrase inhibition enhances the cytostatic effects of Palbociclib
170
Palbociclib exerts its effects on target cells by blocking the activity of the D-type cyclin-dependent 171 kinases CDK4/6 and subsequently inducing a G1 cell cycle arrest 32 . To understand how the combination of CDK4/6 and TNKS inhibition could lead to reduced cell growth in epithelial cells, we analyzed cell 173 cycle kinetics in XAV and Palbociclib treated DLD1 cells. As expected, Palbociclib treatment caused 174 a reduction in the proportion of cells in S-phase and a corresponding increase in the in the percentage 175 of cells in G0/G1 (Fig 4a-b ). Combined treatment with XAV caused a further drop in S-phase cells, 176 resulting in more than 70% of cells arrested in G0/G1. 
192
Previous in vitro and in vivo studies have shown that inhibition of either MEK1/2, EGFR, or AKT can 193 enhance the effect of TNKS blockade 17, 19, 20 . To our surprise, we identified only two genes whose 194 depletion synergized with TNKS inhibition: EGFR and CDK4. Though we did identify EGFR as a 195 synthetic interaction with TNKS in DLD1 cells, neither MEK nor AKT scored. As DLD1 cells are 196 sensitive to combined treatment with TNKS and MEK inhibitors (Fig 1c) 17 , we expect that the failure 
214
In addition to identifying synergies with TNKS inhibition, our screen also revealed some possible CRC-215 selective dependencies. In particular, we identified a small set of genes (in particular VRK1, CSNK1A1, 216 and PIK3R4) that were more dramatically depleted in colorectal cancer cell lines, than a range of 217 leukemia, liver and pancreatic cancer cell lines 22 . There is limited in vivo data in the literature to assess 218 whether these represent practical therapeutic targets, though mouse studies have shown that 219 hypomorphic VRK1 animals are viable 33 , and ablation of Csnk1a1 throughout the intestine does not 220 disrupt normal homeostatic functions 34 . Further, while PIK3R4 deletion is embryonic lethal, it is not 221 essential in all adult tissues 35 . Further work will be necessary to determine the requirement for these 222 genes in normal and transformed adult tissues.
223
TNKS inhibitors are often considered direct WNT targeting drugs, though TNKS has many cellular 224 targets in addition to AXIN1/2. In fact, Wang et al 27 , recently reported that the synergy between TNKS 225 and EGFR inhibition in lung cancer cells is due to reduction of YAP/TAZ-mediated signaling via regulation of AMOT proteins 27 . In contrast, our data in colorectal cancer cell lines, suggests that 227 downstream induction of the WNT pathway by activating mutations in CTNNB1 are sufficient to 228 overcome the effects of TNKS blockade. Thus, at least in the CRC cells examined here, WNT pathway 229 inhibition is a critical component of TNKS-mediated growth suppression. It is possible that genetic or 230 cell type-specific differences underlie the differential dependencies of TNKS targeting, but the data 231 imply that TNKS enzymes act to support oncogenic transformation through multiple independent 232 mechanisms. Hence, while TNKS inhibitors may not always provide significant anti-cancer responses 233 as single agents 17, 20 , they may prove effective as part of specific treatment combinations, such as those 234 described here and elsewhere 23 . [39] [40] [41] [42] . In some contexts, secreted factors from senescent cells recruit NK 247 cells, resulting in tumor cell elimination [43] [44] [45] , while in others, the infiltration of monocytes and 248 granulocytes are the primary driver of senescent cell clearance 46 . In separate work, WNT 249 hyperactivation has been directly linked to immunotherapy failure [47] [48] [49] . It will be important to determine 
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Cloning 313 gRNAs were cloned into LRG or LRT2B lentiviral backbones using BsmBI restriction sites and 314 adapters as described elsewhere 22, 31 . All the primers and plasmids are listed in Table 5 .
Lentiviral transduction
293T cells were seeded at 90% confluence into 35mm dishes; 16h later, cells were transfected using 317 PEI as follows: 5ug plasmid, 2.5ug PAX2 packaging vector and 1.25ug VSVg pseudotyping vector 318 were mixed into 150ul DMEM, vortexed 5 seconds and 30ul PEI were added and vortexed again; after 319 15min incubation at RT, transfection mix was added dropwise by swirling the 293T cell plates. 24h 320 later, the medium was replaced with collection medium, and viral supernatants were collected three 321 times every 24h, pooled and preserved in 0.5ml aliquots at -80C indefinitely. Target cells were seeded 322 at 50,000 cells per well of a 12-well plate, and 24h later the viral supernatant dilution containing 8ug/ml 323 polybrene was added. 24h later the infection media was replaced with fresh media and cells were 324 assayed or selected 48h post-transduction. Supplementary Fig 3 | Foronda et 
Relative Cell Growth
Competition assays , SW480 b. HCT116 cells treated with the indicated doses of XAV and Palbociclib were seeded in colony-forming assays. c. Quantification of cell proliferation inhibition in HCT116 cells treated with the indicated concentrations of Palbociclib or Gefitinib +/-XAV. d. shRNA-mediated knock-down of TNKS does not influence cellular sensitivity to Palbociclib, Trametinib or Gefitinib in HCT116 cells. e. Quantification of the experiment shown in (d). f. Trametinib sensitivity in DLD1 parental or base-editing-generated S45F mutant isogenic DLD1 cell lines.
